Identification

Name
Vinblastine
Accession Number
DB00570  (APRD00708)
Type
Small Molecule
Groups
Approved
Description

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Structure
Thumb
Synonyms
  • Vinblastin
  • Vinblastina
  • Vinblastine
  • Vinblastinum
  • Vincaleukoblastine
External IDs
NSC-47842
Product Ingredients
IngredientUNIICASInChI Key
Vinblastine sulfateN00W22YO2B143-67-9KDQAABAKXDWYSZ-PNYVAJAMSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Velbe 1mg/mlPowder, for solution10 mgIntravenousEli Lilly & Co. Ltd.1994-11-152000-10-02Canada
Vinblastine Sulfate Inj 1mg/mlLiquid1 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1992-12-311998-08-13Canada
Vinblastine Sulfate InjectionSolution1 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Vinblastine Sulfate InjectionSolution1 mgIntravenousPfizer1998-04-14Not applicableCanada
Vinblastine Sulphate InjectionSolution1 mgIntravenousTeva2013-02-08Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vinblastine SulfateInjection1 mg/mLIntravenousFresenius Kabi2000-07-12Not applicableUs
International/Other Brands
Blastivin (Pharmachemie) / Cytoblastin (Cipla) / Lemblastine / Oncostin (Cipla) / Velban (ABL Antibióticos do Brasil) / Velbastin (Korea United Pharm) / Velbe (STADA) / Vinblasin (Teva) / Vinblastin (Gedeon Richter) / Vinko (Koçak) / Weibaoding (Hospira) / Xintoprost (Richmond)
Categories
UNII
5V9KLZ54CY
CAS number
865-21-4
Weight
Average: 810.9741
Monoisotopic: 810.420379474
Chemical Formula
C46H58N4O9
InChI Key
JXLYSJRDGCGARV-CFWMRBGOSA-N
InChI
InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
[H][[email protected]@]12N(C)C3=CC(OC)=C(C=C3[[email protected]@]11CCN3CC=C[[email protected]](CC)([[email protected]@]13[H])[[email protected]@]([H])(OC(C)=O)[[email protected]]2(O)C(=O)OC)[[email protected]]1(C[[email protected]@]2([H])CN(C[[email protected]](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC

Pharmacology

Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Structured Indications
Pharmacodynamics

Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Mechanism of action

The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.

TargetActionsOrganism
ATubulin alpha-1A chain
adduct
Human
ATubulin beta chain
adduct
Human
ATubulin delta chain
adduct
Human
ATubulin gamma-1 chain
adduct
Human
ATubulin epsilon chain
adduct
Human
NTranscription factor AP-1
other/unknown
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

98-99%

Metabolism

Hepatic. Metabolism of vinblastine has been shown to be mediated by hepatic cytochrome P450 3A isoenzymes.

Route of elimination

The major route of excretion may be through the biliary system.

Half life

Triphasic: 35 min, 53 min, and 19 hours

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 423 mg/kg; Oral, rat: LD50 = 305 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Vinblastine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Vinblastine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Vinblastine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Vinblastine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vinblastine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Vinblastine.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Vinblastine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Vinblastine.Approved
AlbendazoleThe serum concentration of Vinblastine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Vinblastine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Vinblastine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Vinblastine can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Vinblastine.Approved, Investigational
AmantadineThe serum concentration of Vinblastine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Vinblastine.Approved, Investigational
Aminohippuric acidThe serum concentration of Vinblastine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Vinblastine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Vinblastine.Approved
AmlodipineThe serum concentration of Vinblastine can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Vinblastine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Vinblastine can be increased when it is combined with Amsacrine.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Vinblastine.Approved
AprepitantThe serum concentration of Vinblastine can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vinblastine.Approved, Investigational
ArtemetherThe metabolism of Vinblastine can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Vinblastine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Vinblastine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Vinblastine.Approved
AtomoxetineThe metabolism of Vinblastine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Vinblastine is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Vinblastine.Approved, Investigational
AzelastineThe serum concentration of Vinblastine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Vinblastine can be increased when it is combined with Azithromycin.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Vinblastine.Investigational
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Vinblastine.Approved, Investigational
BenzocaineThe serum concentration of Vinblastine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Vinblastine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Vinblastine.Approved, Vet Approved
BetaxololThe metabolism of Vinblastine can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Vinblastine.Approved, Investigational
BiperidenThe serum concentration of Vinblastine can be increased when it is combined with Biperiden.Approved
BoceprevirThe metabolism of Vinblastine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Vinblastine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vinblastine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Vinblastine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vinblastine.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Vinblastine.Approved, Investigational
BuprenorphineThe serum concentration of Vinblastine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Vinblastine can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Vinblastine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinblastine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Vinblastine.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Vinblastine.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Vinblastine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Vinblastine.Approved
Candesartan cilexetilThe serum concentration of Vinblastine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Vinblastine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Vinblastine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Vinblastine can be increased when it is combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Vinblastine.Approved
CarvedilolThe serum concentration of Vinblastine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Vinblastine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Vinblastine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Vinblastine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Vinblastine.Withdrawn
ChloroquineThe serum concentration of Vinblastine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vinblastine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Vinblastine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Vinblastine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Vinblastine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Vinblastine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidVinblastine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilazaprilThe serum concentration of Vinblastine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Vinblastine can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Vinblastine can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Vinblastine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Vinblastine.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Vinblastine.Approved
ClarithromycinThe metabolism of Vinblastine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Vinblastine can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Vinblastine.Approved, Illicit
ClofazimineThe serum concentration of Vinblastine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Vinblastine.Approved, Investigational
ClomipramineThe serum concentration of Vinblastine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Vinblastine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Vinblastine.Approved, Nutraceutical
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vinblastine.Approved
ClotrimazoleThe metabolism of Vinblastine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Clozapine.Approved
CobicistatThe serum concentration of Vinblastine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Vinblastine.Approved
CocaineThe metabolism of Vinblastine can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Vinblastine.Approved
ColforsinThe serum concentration of Vinblastine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Vinblastine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Vinblastine.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Vinblastine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vinblastine.Approved
CrizotinibThe metabolism of Vinblastine can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vinblastine.Approved, Investigational
CyclosporineThe metabolism of Vinblastine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Vinblastine.Experimental
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vinblastine.Approved
DabrafenibThe serum concentration of Vinblastine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Vinblastine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Vinblastine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Vinblastine.Approved
DarifenacinThe metabolism of Vinblastine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Vinblastine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Vinblastine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Vinblastine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Vinblastine.Approved
DeferasiroxThe serum concentration of Vinblastine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Vinblastine can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vinblastine.Approved
DesipramineThe serum concentration of Vinblastine can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vinblastine.Approved
DesloratadineThe serum concentration of Vinblastine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Vinblastine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Vinblastine can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Vinblastine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Vinblastine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vinblastine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vinblastine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Vinblastine.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Vinblastine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Vinblastine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Vinblastine.Experimental
DihydroergotamineThe metabolism of Vinblastine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Vinblastine.Illicit
DiltiazemThe metabolism of Vinblastine can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Vinblastine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Vinblastine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinblastine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Vinblastine.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Vinblastine can be decreased when combined with Dosulepin.Approved
DoxazosinThe serum concentration of Vinblastine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Vinblastine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Vinblastine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Vinblastine.Approved, Investigational
DoxycyclineThe metabolism of Vinblastine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Vinblastine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Vinblastine can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Vinblastine can be decreased when combined with Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Vinblastine.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Vinblastine.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Vinblastine.Approved, Investigational
EliglustatThe metabolism of Vinblastine can be decreased when combined with Eliglustat.Approved
EnalaprilThe serum concentration of Vinblastine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Vinblastine.Approved
EnzalutamideThe serum concentration of Vinblastine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Vinblastine.Approved, Investigational
ErgonovineThe serum concentration of Vinblastine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Vinblastine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Vinblastine.Approved, Investigational
ErythromycinThe serum concentration of Vinblastine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Vinblastine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Vinblastine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Vinblastine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Vinblastine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vinblastine.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Vinblastine.Approved
EtravirineThe serum concentration of Vinblastine can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Vinblastine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Vinblastine.Approved
FelodipineThe serum concentration of Vinblastine can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Vinblastine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinblastine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Vinblastine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Vinblastine.Approved
FingolimodVinblastine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe metabolism of Vinblastine can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Vinblastine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Vinblastine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Vinblastine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Vinblastine can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Vinblastine.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Vinblastine.Approved
FluvoxamineThe metabolism of Vinblastine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Vinblastine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vinblastine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Vinblastine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Vinblastine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Vinblastine.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Vinblastine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Vinblastine.Approved
GenisteinThe serum concentration of Vinblastine can be increased when it is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Vinblastine.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Vinblastine.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Vinblastine.Approved
GlyburideThe serum concentration of Vinblastine can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Vinblastine can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Vinblastine can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Vinblastine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Vinblastine.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Vinblastine.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Vinblastine.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Vinblastine.Approved
IdelalisibThe serum concentration of Vinblastine can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Vinblastine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Vinblastine.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Vinblastine.Approved
IndinavirThe metabolism of Vinblastine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Vinblastine.Approved, Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Vinblastine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Vinblastine.Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Vinblastine.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Vinblastine.Approved, Investigational
IsavuconazoniumThe metabolism of Vinblastine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Vinblastine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Vinblastine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Vinblastine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Vinblastine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Vinblastine.Approved, Vet Approved
JosamycinThe serum concentration of Vinblastine can be increased when it is combined with Josamycin.Approved
KetamineThe serum concentration of Vinblastine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Vinblastine.Approved
KetoconazoleThe metabolism of Vinblastine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Vinblastine can be increased when it is combined with Kitasamycin.Experimental
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Vinblastine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Vinblastine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Vinblastine.Experimental
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Vinblastine.Approved, Investigational
LapatinibThe serum concentration of Vinblastine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Vinblastine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Vinblastine is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Vinblastine.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Vinblastine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Vinblastine.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Vinblastine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Vinblastine.Approved
LevothyroxineThe serum concentration of Vinblastine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Vinblastine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Vinblastine.Approved
LiothyronineThe serum concentration of Vinblastine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Vinblastine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Vinblastine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Vinblastine.Approved
LomitapideThe serum concentration of Vinblastine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Vinblastine.Approved
LopinavirThe serum concentration of Vinblastine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Vinblastine can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Vinblastine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Vinblastine.Approved
LovastatinThe metabolism of Vinblastine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Vinblastine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Vinblastine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Vinblastine can be decreased when combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Vinblastine.Illicit, Withdrawn
ManidipineThe metabolism of Vinblastine can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Vinblastine.Approved, Investigational
MaprotilineThe serum concentration of Vinblastine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Vinblastine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Vinblastine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Vinblastine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Vinblastine can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Vinblastine.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Vinblastine.Experimental
MethadoneThe serum concentration of Vinblastine can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Vinblastine.Approved
MethotrimeprazineThe metabolism of Vinblastine can be decreased when combined with Methotrimeprazine.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Vinblastine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Vinblastine.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Vinblastine.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Vinblastine.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Vinblastine.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Vinblastine.Experimental
MibefradilThe serum concentration of Vinblastine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Vinblastine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Vinblastine can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Vinblastine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Vinblastine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Vinblastine.Approved
MitomycinThe risk or severity of adverse effects can be increased when Vinblastine is combined with Mitomycin.Approved
MitotaneThe serum concentration of Vinblastine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Vinblastine.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Vinblastine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vinblastine.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Vinblastine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Vinblastine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Vinblastine.Approved, Vet Approved
NaltrexoneThe serum concentration of Vinblastine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Vinblastine can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Vinblastine is combined with Natalizumab.Approved, Investigational
NefazodoneThe metabolism of Vinblastine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Vinblastine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Vinblastine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Vinblastine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Vinblastine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Vinblastine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Vinblastine.Approved
NifedipineThe serum concentration of Vinblastine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Vinblastine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Vinblastine.Approved
NisoldipineThe serum concentration of Vinblastine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Vinblastine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Vinblastine can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Vinblastine.Approved
NorethisteroneThe serum concentration of Vinblastine can be decreased when it is combined with Norethisterone.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Vinblastine.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Vinblastine.Approved, Investigational
OlaparibThe metabolism of Vinblastine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Vinblastine can be increased when it is combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Vinblastine.Experimental
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Vinblastine.Approved
OmeprazoleThe serum concentration of Vinblastine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Vinblastine can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Vinblastine.Approved
P-NitrophenolThe serum concentration of Vinblastine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vinblastine.Approved, Vet Approved
PalbociclibThe serum concentration of Vinblastine can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Vinblastine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Vinblastine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Vinblastine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe metabolism of Vinblastine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vinblastine.Approved
Peginterferon alfa-2bThe serum concentration of Vinblastine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Vinblastine can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Vinblastine.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Vinblastine can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Vinblastine.Experimental
PhenobarbitalThe metabolism of Vinblastine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Vinblastine can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Vinblastine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinblastine.Approved, Investigational
PimozideThe serum concentration of Vinblastine can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Vinblastine.Approved
Platelet Activating FactorThe serum concentration of Vinblastine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Vinblastine.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Vinblastine.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vinblastine.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Vinblastine.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Vinblastine.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Vinblastine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Vinblastine.Approved, Vet Approved
PrimidoneThe metabolism of Vinblastine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Vinblastine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Vinblastine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Vinblastine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Vinblastine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Vinblastine can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Vinblastine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Vinblastine.Experimental
ProtriptylineThe serum concentration of Vinblastine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Vinblastine.Approved
QuercetinThe serum concentration of Vinblastine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Vinblastine.Approved
QuinacrineThe serum concentration of Vinblastine can be increased when it is combined with Quinacrine.Approved
QuinidineThe metabolism of Vinblastine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Vinblastine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Vinblastine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vinblastine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Vinblastine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Vinblastine.Approved, Investigational
ReboxetineThe serum concentration of Vinblastine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Vinblastine can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Vinblastine can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Vinblastine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Vinblastine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Vinblastine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Vinblastine.Approved, Investigational
RilpivirineThe serum concentration of Vinblastine can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Vinblastine.Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Vinblastine.Approved, Investigational
RitonavirThe serum concentration of Vinblastine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Vinblastine.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Vinblastine.Approved
RolapitantThe serum concentration of Vinblastine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Vinblastine.Approved, Investigational
RopiniroleThe metabolism of Vinblastine can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Vinblastine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Vinblastine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Vinblastine.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Vinblastine.Approved, Vet Approved
SaquinavirThe metabolism of Vinblastine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Vinblastine can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Vinblastine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Vinblastine.Approved
SertralineThe serum concentration of Vinblastine can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Vinblastine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vinblastine.Approved
SiltuximabThe serum concentration of Vinblastine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Vinblastine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Vinblastine can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vinblastine.Approved
SirolimusThe serum concentration of Vinblastine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Vinblastine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Vinblastine.Approved
SolithromycinThe serum concentration of Vinblastine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Vinblastine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Vinblastine.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Vinblastine.Experimental
SpiramycinThe serum concentration of Vinblastine can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe serum concentration of Vinblastine can be increased when it is combined with Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Vinblastine.Investigational
St. John's WortThe serum concentration of Vinblastine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Vinblastine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Vinblastine can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Vinblastine can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Vinblastine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Vinblastine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Vinblastine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Vinblastine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Vinblastine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinblastine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Vinblastine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Vinblastine.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Vinblastine.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Vinblastine.Approved
TelaprevirThe metabolism of Vinblastine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Vinblastine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Vinblastine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Vinblastine.Approved
TerazosinThe serum concentration of Vinblastine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Vinblastine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Vinblastine can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Vinblastine.Experimental
TesmilifeneThe serum concentration of Vinblastine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Vinblastine can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Vinblastine.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Vinblastine.Withdrawn
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Vinblastine.Approved
TiclopidineThe metabolism of Vinblastine can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Vinblastine.Approved
TipranavirThe metabolism of Vinblastine can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Vinblastine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibVinblastine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Vinblastine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Vinblastine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vinblastine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Vinblastine.Approved, Investigational
TranylcypromineThe metabolism of Vinblastine can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vinblastine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Vinblastine.Approved
TrazodoneThe serum concentration of Vinblastine can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Vinblastine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Vinblastine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Vinblastine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Vinblastine can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Vinblastine can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Vinblastine can be increased when it is combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Vinblastine.Experimental
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Vinblastine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Vinblastine.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Vinblastine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Vinblastine.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Vinblastine.Approved
VenlafaxineThe metabolism of Vinblastine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Vinblastine can be decreased when combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Vinblastine.Approved, Investigational
VinorelbineThe serum concentration of Vinblastine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Vinblastine.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vinblastine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Vinblastine.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Vinblastine.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Vinblastine.Approved
ZimelidineThe serum concentration of Vinblastine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Vinblastine can be decreased when combined with Ziprasidone.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Vinblastine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Pierre Potier, Pierre Mangeney, Nicole Langlois, Yves Langlois, "Process for the synthesis of vinblastine and leurosidine." U.S. Patent US4305875, issued October, 1977.

US4305875
General References
  1. Starling D: Two ultrastructurally distinct tubulin paracrystals induced in sea-urchin eggs by vinblastine sulphate. J Cell Sci. 1976 Jan;20(1):79-89. [PubMed:942954]
External Links
ChemSpider
12773
BindingDB
50012278
ChEMBL
CHEMBL159
Therapeutic Targets Database
DAP000785
PharmGKB
PA451877
HET
VLB
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vinblastine
ATC Codes
L01CA01 — Vinblastine
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1z2b / 4eb6 / 5bmv / 5j2t
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentLymphoma, Hodgkins1
1CompletedTreatmentBrain and Central Nervous System Tumors / Neurofibromatosis Type 11
1CompletedTreatmentHodgkins Disease (HD)1
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Kidney1
1CompletedTreatmentStage IV Melanoma1
1CompletedTreatmentTumors, Central Nervous System / Tumors, Solid1
1RecruitingTreatmentCentral Nervous System / Recurrent Lymphoma / Refractory Lymphomas / Tumors, Solid1
1RecruitingTreatmentHodgkins Disease (HD)1
1RecruitingTreatmentLymphoma, Hodgkins1
1RecruitingTreatmentRecurrent Low-grade Gliomas / Refractory Low-grade Gliomas1
1Unknown StatusTreatmentLung Cancers2
1, 2CompletedTreatmentHodgkins Disease (HD)1
1, 2CompletedTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentRecurrent Melanoma / Stage IV Skin Melanoma1
1, 2RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / CD30-Positive Neoplastic Cells Present / Classical Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage III Hodgkin Lymphoma / Stage IIIA Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2Active Not RecruitingTreatmentGliomas1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentLymphoma, Hodgkins5
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentBladder Cancers2
2CompletedTreatmentBladder Cancers / Muscle-invasive Bladder Cancer1
2CompletedTreatmentDesmoid Tumors1
2CompletedTreatmentGliomas1
2CompletedTreatmentHigh Risk Urothelial Carcinoma of the Upper Urinary Tracts / Muscle Invasive Bladder Cancer1
2CompletedTreatmentHodgkins Disease (HD) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentIntraluminal Pulmonary Vein Stenosis1
2CompletedTreatmentMalignant Lymphomas8
2CompletedTreatmentMelanoma / Skin Cancers1
2CompletedTreatmentNeurofibromatosis Type 1 / Precancerous Conditions1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentSarcomas1
2Not Yet RecruitingTreatmentClassical Hodgkin Lymphoma / Lymphocyte-Depleted Classical Hodgkin Lymphoma / Lymphocyte-Rich Classical Hodgkin Lymphoma / Mixed Cellularity Classical Hodgkin Lymphoma / Nodular Sclerosis Classical Hodgkin Lymphoma1
2Not Yet RecruitingTreatmentStage I Hodgkin Lymphoma / Stage IA Hodgkin Lymphoma / Stage IB Hodgkin Lymphoma / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentClassical Hodgkin Lymphoma2
2RecruitingTreatmentHIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2RecruitingTreatmentLocalized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter1
2RecruitingTreatmentLow Grade Glioma (LGG)1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRecurrent Low-grade Gliomas / Refractory Low-grade Gliomas1
2RecruitingTreatmentTumors, Solid1
2RecruitingTreatmentUrothelial Carcinoma of the Bladder1
2TerminatedTreatmentBladder Cancers3
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLymphoma, Hodgkins1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMelanoma1
2TerminatedTreatmentMetastatic Melanoma1
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentHodgkins Disease (HD)1
2Unknown StatusTreatmentMalignant Lymphomas3
2Unknown StatusTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentRenal Cancers1
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2, 3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2, 3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
3Active Not RecruitingTreatmentLymphoma, Hodgkins3
3Active Not RecruitingTreatmentMalignant Lymphomas5
3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
3CompletedTreatmentBladder Cancers / Urethral Cancer1
3CompletedTreatmentCervical Cancers1
3CompletedTreatmentElderly Patients (>65 Years) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentHodgkins Disease (HD)1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLung Cancers3
3CompletedTreatmentLymphoma, Hodgkins4
3CompletedTreatmentMalignant Lymphomas3
3CompletedTreatmentMelanoma (Skin)2
3CompletedTreatmentMelanoma / Skin Cancers1
3CompletedTreatmentProstate Cancer2
3CompletedTreatmentStage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
3RecruitingTreatmentLymphoma, Hodgkins1
3TerminatedTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentProstate Cancer1
3Unknown StatusTreatmentBladder Cancers1
3Unknown StatusTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3Unknown StatusTreatmentLung Cancers3
3Unknown StatusTreatmentLymphoma, Hodgkins1
3Unknown StatusTreatmentMalignant Lymphomas3
4RecruitingTreatmentMalignant Lymphomas1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentChildhood Langerhans Cell Histiocytosis1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas2

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous10 mg
InjectionIntravenous1 mg/mL
LiquidIntravenous1 mg
SolutionIntravenous1 mg
Prices
Unit descriptionCostUnit
Vinblastine sulf 10 mg vial18.6USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)267 °CNot Available
water solubilityNegligibleNot Available
logP3.70SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0169 mg/mLALOGPS
logP4.22ALOGPS
logP4.18ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)10.87ChemAxon
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area154.1 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity222.42 m3·mol-1ChemAxon
Polarizability87.81 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9806
Blood Brain Barrier-0.9203
Caco-2 permeable+0.6283
P-glycoprotein substrateSubstrate0.9213
P-glycoprotein inhibitor IInhibitor0.7737
P-glycoprotein inhibitor IIInhibitor0.6817
Renal organic cation transporterNon-inhibitor0.771
CYP450 2C9 substrateNon-substrate0.816
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.72
CYP450 1A2 substrateNon-inhibitor0.9198
CYP450 2C9 inhibitorNon-inhibitor0.9093
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8149
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.91
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9111 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9366
hERG inhibition (predictor II)Non-inhibitor0.5793
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Vinca alkaloids
Sub Class
Not Available
Direct Parent
Vinca alkaloids
Alternative Parents
Carbazoles / 3-alkylindoles / Tricarboxylic acids and derivatives / Anisoles / Dialkylarylamines / Alkyl aryl ethers / Aralkylamines / Piperidines / N-alkylpyrrolidines / Tertiary alcohols
show 12 more
Substituents
Vinca alkaloid skeleton / Carbazole / 3-alkylindole / Tricarboxylic acid or derivatives / Indole or derivatives / Indole / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Anisole / Aralkylamine
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Adduct
General Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Specific Function
Gtp binding
Gene Name
TUBA1A
Uniprot ID
Q71U36
Uniprot Name
Tubulin alpha-1A chain
Molecular Weight
50135.25 Da
References
  1. Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. [PubMed:18220533]
  2. Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991 Nov;52(2):127-47. [PubMed:1818332]
  3. Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96. [PubMed:9664292]
  4. Islam MN, Iskander MN: Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem. 2004 Dec;4(10):1077-104. [PubMed:15579115]
  5. Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem. 2003 Nov;253(1-2):41-7. [PubMed:14619954]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Adduct
General Function
Ubiquitin protein ligase binding
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBB
Uniprot ID
P07437
Uniprot Name
Tubulin beta chain
Molecular Weight
49670.515 Da
References
  1. Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. [PubMed:18220533]
  2. Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991 Nov;52(2):127-47. [PubMed:1818332]
  3. Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96. [PubMed:9664292]
  4. Islam MN, Iskander MN: Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem. 2004 Dec;4(10):1077-104. [PubMed:15579115]
  5. Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem. 2003 Nov;253(1-2):41-7. [PubMed:14619954]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Adduct
General Function
Structural constituent of cytoskeleton
Specific Function
In the elongating spermatid it is associated with the manchette, a specialized microtubule system present during reshaping of the sperm head.
Gene Name
TUBD1
Uniprot ID
Q9UJT1
Uniprot Name
Tubulin delta chain
Molecular Weight
51033.86 Da
References
  1. Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. [PubMed:18220533]
  2. Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991 Nov;52(2):127-47. [PubMed:1818332]
  3. Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96. [PubMed:9664292]
  4. Islam MN, Iskander MN: Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem. 2004 Dec;4(10):1077-104. [PubMed:15579115]
  5. Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem. 2003 Nov;253(1-2):41-7. [PubMed:14619954]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Adduct
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. The gamma chain is found at microtubule organizing centers (MTOC) such as the spindle poles or the centrosome. Pericentriolar matrix component that...
Gene Name
TUBG1
Uniprot ID
P23258
Uniprot Name
Tubulin gamma-1 chain
Molecular Weight
51169.48 Da
References
  1. Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. [PubMed:18220533]
  2. Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991 Nov;52(2):127-47. [PubMed:1818332]
  3. Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96. [PubMed:9664292]
  4. Islam MN, Iskander MN: Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem. 2004 Dec;4(10):1077-104. [PubMed:15579115]
  5. Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem. 2003 Nov;253(1-2):41-7. [PubMed:14619954]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Adduct
General Function
Structural constituent of cytoskeleton
Specific Function
Not Available
Gene Name
TUBE1
Uniprot ID
Q9UJT0
Uniprot Name
Tubulin epsilon chain
Molecular Weight
52931.4 Da
References
  1. Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. [PubMed:18220533]
  2. Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991 Nov;52(2):127-47. [PubMed:1818332]
  3. Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96. [PubMed:9664292]
  4. Islam MN, Iskander MN: Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem. 2004 Dec;4(10):1077-104. [PubMed:15579115]
  5. Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem. 2003 Nov;253(1-2):41-7. [PubMed:14619954]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expre...
Gene Name
JUN
Uniprot ID
P05412
Uniprot Name
Transcription factor AP-1
Molecular Weight
35675.32 Da
References
  1. Brantley-Finley C, Lyle CS, Du L, Goodwin ME, Hall T, Szwedo D, Kaushal GP, Chambers TC: The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol. 2003 Aug 1;66(3):459-69. [PubMed:12907245]
  2. Bene A, Kurten RC, Chambers TC: Subcellular localization as a limiting factor for utilization of decoy oligonucleotides. Nucleic Acids Res. 2004 Oct 21;32(19):e142. [PubMed:15498923]
  3. Obey TB, Lyle CS, Chambers TC: Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine. Biochem Biophys Res Commun. 2005 Oct 7;335(4):1179-84. [PubMed:16111654]
  4. Martinez-Campa C, Casado P, Rodriguez R, Zuazua P, Garcia-Pedrero JM, Lazo PS, Ramos S: Effect of vinca alkaloids on ERalpha levels and estradiol-induced responses in MCF-7 cells. Breast Cancer Res Treat. 2006 Jul;98(1):81-9. Epub 2006 Mar 23. [PubMed:16555127]
  5. Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, Chambers TC: Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol. 2007 Feb 15;73(4):481-90. Epub 2006 Oct 29. [PubMed:17126817]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Arora A, Shukla Y: Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett. 2003 Jan 28;189(2):167-73. [PubMed:12490309]
  2. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  4. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  5. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153]
  6. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  7. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5. [PubMed:1359120]
  8. Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78. [PubMed:8862725]
  9. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059]
  10. Smit JW, Weert B, Schinkel AH, Meijer DK: Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther. 1998 Jul;286(1):321-7. [PubMed:9655875]
  11. Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH: Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol. 1998 Sep 15;56(6):719-27. [PubMed:9751076]
  12. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141]
  13. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169]
  14. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  15. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  16. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899]
  17. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  18. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. [PubMed:12604693]
  19. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol. 2003 Sep;285(3):C584-91. Epub 2003 Apr 30. [PubMed:12724138]
  20. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  21. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039]
  22. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75. [PubMed:14706813]
  23. Hunter J, Hirst BH, Simmons NL: Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res. 1993 May;10(5):743-9. [PubMed:8100632]
  24. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716]
  25. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA: Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999 Aug;290(2):854-62. [PubMed:10411602]
  26. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
  27. Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC: P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90. [PubMed:14991868]
  28. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783]
  29. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272]
  30. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439]
  31. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050]
  32. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol. 2002 May;61(5):974-81. [PubMed:11961114]
  33. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K: Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull. 2002 Jun;25(6):771-8. [PubMed:12081145]
  34. Henning U, Loffler S, Krieger K, Klimke A: Uptake of clozapine into HL-60 promyelocytic leukaemia cells. Pharmacopsychiatry. 2002 May;35(3):90-5. [PubMed:12107852]
  35. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
  36. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
  2. Loe DW, Almquist KC, Cole SP, Deeley RG: ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 1996 Apr 19;271(16):9683-9. [PubMed:8621644]
  3. Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ: Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002;64(3):126-34. [PubMed:11834888]
  4. Yildiz M, Celik-Ozenci C, Akan S, Akan I, Sati L, Demir R, Savas B, Ozben T, Samur M, Ozdogan M, Artac M, Bozcuk H: Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study. Cell Biol Int. 2006 Mar;30(3):278-82. Epub 2006 Feb 2. [PubMed:16458542]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
  2. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  3. Ishikawa T, Muller M, Klunemann C, Schaub T, Keppler D: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem. 1990 Nov 5;265(31):19279-86. [PubMed:2172249]
  4. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
  5. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4...
Gene Name
ABCC6
Uniprot ID
O95255
Uniprot Name
Multidrug resistance-associated protein 6
Molecular Weight
164904.81 Da
References
  1. Cai J, Daoud R, Alqawi O, Georges E, Pelletier J, Gros P: Nucleotide binding and nucleotide hydrolysis properties of the ABC transporter MRP6 (ABCC6). Biochemistry. 2002 Jun 25;41(25):8058-67. [PubMed:12069597]
Details
5. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci. 1999 Feb;47(2):181-6. [PubMed:10220855]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13